CTLA4 and neoplasm: To ensure a controlled activity of the antibody in the TME and to decouple antitumor efficacy from immunotherapy-related toxicity, a CTLA-4 dual variable domain immunoglobulin (anti-CTLA-4 DVD) was developed where the inner anti-CTLA-4 binding domain is shielded by an outer tumor-targeting domain (106).